PURPOSE: Beckwith-Wiedemann Syndrome is caused by defects in imprinted gene expression at 11p15. Currently, quantitative Southern analysis using DNA methylation-sensitive restriction enzymes is used in molecular diagnosis of this syndrome. METHODS: We describe a rapid and highly quantitative test for assessing DNA methylation at 11p15 using sodium bisulfite treatment of genomic DNA coupled with quantitative TaqMan methylation-sensitive polymerase chain reaction. RESULTS: TaqMan MSP can assess DNA methylation at both differentially methylated region (DMR)1 and DMR2 at 11p15. In addition, by using TaqMan MSP we were able to determine the parent of origin of a duplication of 11p15 by quantification of both DMR1 and DMR2 DNA methylation. CONCLUSION: TaqMan MSP method is a robust and rapid method for detecting changes in DNA methylation that compares favorably to the current standard of Southern blot for DNA methylation analysis. Assessment of DMR1 and DMR2 provides the most comprehensive assay for methylation defects in Beckwith Wiedemann Syndrome, accounting for more than 70% of the cases. The advantages of TaqMan MSP are that it requires less DNA and that it is rapid, less labor-intensive, and amenable to high-throughput analysis. Moreover, this approach can be modified to assess DNA methylation changes anywhere in the genome.
PURPOSE: Beckwith-Wiedemann Syndrome is caused by defects in imprinted gene expression at 11p15. Currently, quantitative Southern analysis using DNA methylation-sensitive restriction enzymes is used in molecular diagnosis of this syndrome. METHODS: We describe a rapid and highly quantitative test for assessing DNA methylation at 11p15 using sodium bisulfite treatment of genomic DNA coupled with quantitative TaqMan methylation-sensitive polymerase chain reaction. RESULTS: TaqMan MSP can assess DNA methylation at both differentially methylated region (DMR)1 and DMR2 at 11p15. In addition, by using TaqMan MSP we were able to determine the parent of origin of a duplication of 11p15 by quantification of both DMR1 and DMR2 DNA methylation. CONCLUSION: TaqMan MSP method is a robust and rapid method for detecting changes in DNA methylation that compares favorably to the current standard of Southern blot for DNA methylation analysis. Assessment of DMR1 and DMR2 provides the most comprehensive assay for methylation defects in Beckwith Wiedemann Syndrome, accounting for more than 70% of the cases. The advantages of TaqMan MSP are that it requires less DNA and that it is rapid, less labor-intensive, and amenable to high-throughput analysis. Moreover, this approach can be modified to assess DNA methylation changes anywhere in the genome.
Authors: Jochen K Lennerz; Robert J Timmerman; Dorothy K Grange; Michael R DeBaun; Andrew P Feinberg; Barbara A Zehnbauer Journal: J Mol Diagn Date: 2010-07-08 Impact factor: 5.568
Authors: Suzanne P MacFarland; Kelly A Duffy; Tricia R Bhatti; Rochelle Bagatell; Naomi J Balamuth; Garrett M Brodeur; Arupa Ganguly; Peter A Mattei; Lea F Surrey; Frank M Balis; Jennifer M Kalish Journal: Pediatr Blood Cancer Date: 2018-06-22 Impact factor: 3.167
Authors: John P Johnson; Linda Beischel; Corbin Schwanke; Katie Styren; Amy Crunk; Jonathan Schoof; Abdallah F Elias Journal: J Assist Reprod Genet Date: 2018-06-24 Impact factor: 3.412
Authors: Elise M Fiala; Michael V Ortiz; Jennifer A Kennedy; Dominik Glodzik; Megan Harlan Fleischut; Kelly A Duffy; Evan R Hathaway; Todd Heaton; Justin T Gerstle; Peter Steinherz; Neerav Shukla; Nicole McNeer; Kaitlyn Tkachuk; Nancy Bouvier; Karen Cadoo; Maria I Carlo; Alicia Latham; Marianne Dubard Gault; Vijai Joseph; Yelena Kemel; Alex Kentsis; Zsofia Stadler; Michael La Quaglia; Elli Papaemmanuil; Danielle Friedman; Arupa Ganguly; Andrew Kung; Kenneth Offit; Jennifer M Kalish; Michael F Walsh Journal: Cancer Date: 2020-04-22 Impact factor: 6.860